| Patent application number | Description | Published |
|---|
| 20080241265 | Pharmaceutical Combinations Containing Lamivudine, Stavudine and Nevirapine - A pharmaceutical composition comprising 10-120 mg lamivudine, 1-30 mg stavudine and 50-170 mg nevirapine for pediatric treatment of viral infections. One particularly preferred composition comprises a tablet containing 12 mg stavudine, 60 mg lamivudine and 100 mg nevirapine. Another particularly preferred composition comprises a second tablet containing 6 mg stavudine, 30 mg lamivudine and 500 mg nevirapine. These compositions are suitable for treating children having a body weight from 5 to 30 kg. | 10-02-2008 |
| 20080251072 | Inhaler Device - An inhaler device ( | 10-16-2008 |
| 20080317852 | Pharmaceutical Combination - A pharmaceutical formulation for the treatment of HIV is provided. The formulation is a combination of a nucleoside reverse transcriptase inhibitor and a nucleotide reverse transcriptase inhibitor in which the combination has an increased stability over prior art combination therapies. The invention also provides a pharmaceutical product containing the formulation. | 12-25-2008 |
| 20090263333 | Pharmaceutical compounds and compositions - The invention provides three polymorphic forms of crystalline levosalbutamol sulphate designated herein as Forms I, II and III. Crystalline levosalbutamol sulphate Form I is characterised by a powder XRD pattern with peaks at 10.8, 11.9, 13.0, 18.3, 28.5±0.2 degrees 2 theta. Crystalline levosalbutamol sulphate Form II is characterised by a powder XRD pattern with peaks at 8.7, 9.6, 15.2, 15.7, 19.1, 27.2, 30.7±0.2 degrees 2 theta. Crystalline levosalbutamol sulphate Form III is characterised by a powder XRD pattern with peaks at 5.5, 6.9, 7.3, 18.7±0.2 degrees 2 theta. Processes for making the new polymorphic forms and pharmaceutical compositions comprising them are also provided. A pharmaceutical composition comprises a therapeutically effective isomer of salbutamol or a salt, solvate, ester, derivative or polymorph thereof, a glucocorticoid and a pharmaceutically acceptable carrier or excipient and optionally one or more other therapeutic agents. Preferably the composition is an aerosol formulation comprising the drugs, a propellant and optionally one or more other ingredients, such as a surfactant, cosolvent, or bulking agent. Alternatively, DPI or inhalation suspensions may be used. | 10-22-2009 |
| 20100126507 | MULTI-DOSE INHALER DEVICE - The present invention provides an inhaler device ( | 05-27-2010 |
| 20100173921 | Antiretroviral Solid Oral Composition - The present invention provides an antiretroviral solid oral composition comprising one or more antiretroviral drugs, for example protease inhibitors such as lopinavir, ritonavir or a combination thereof with one or more excipients. The invention provides a composition which is smaller for a given amount of said active substance and possesses taste masking property and a process for preparing the composition. The present invention also provides an antiretroviral solid oral composition comprising one or more antiretroviral drugs, for example protease inhibitors such as lopinavir, ritonavir or a combination thereof with at least one water insoluble polymer, wherein the ratio of drug to polymer in the composition ranges from about 1:1 to about 1:6, and a process for preparing the composition. | 07-08-2010 |
| 20100275912 | AEROSOL DEVICE - The invention relates to an aerosol device. More specifically the invention relates to an aerosol device for a Metered Dose Inhaler. The aerosol device ( | 11-04-2010 |
| 20110000486 | VALVE FOR AN AEROSOL DEVICE - The invention relates to a valve for an aerosol device. More specifically the invention relates to a valve for an aerosol device for a Metered Dose Inhaler. The valve assembly ( | 01-06-2011 |
